(PDCO) Patterson Companies - Ratings and Ratios

Patterson Companies Inc. (NASDAQ: PDCO) is a leading distributor of dental and animal health products, operating primarily in the U.S., U.K., and Canada. The company is structured into three main segments: Dental, Animal Health, and Corporate. Its Dental segment offers a wide range of consumable products, including infection control materials, restorative dental supplies, and instruments. They also provide advanced dental technology and equipment, as well as practice optimization solutions like practice management software, e-commerce tools, revenue cycle management, and patient engagement systems. Additionally, this segment delivers clinical education and patient education systems, along with services such as software design, equipment maintenance, and financing options.

The Animal Health segment focuses on distributing biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, and nutritional products for both pets and production animals. They also offer a private-label portfolio under brands like Aspen, First Companion, and Patterson Veterinary, catering to veterinarians, producers, and retailers. This segment emphasizes value-added services, making it a one-stop solution for animal health professionals.

The Corporate segment provides customer financing services and manages other miscellaneous products. Patterson Companies serves a diverse customer base, including dentists, laboratories, institutions, veterinarians, animal health professionals, and retailers. Founded in 1877, the company has a long history of adapting to industry needs. It rebranded from Patterson Dental Company to Patterson Companies Inc. in 2004 to reflect its expanded scope. Headquartered in Saint Paul, Minnesota, the company has established itself as a reliable partner in healthcare distribution.

From a financial perspective, Patterson Companies has a market capitalization of $2.7 billion, with a trailing P/E ratio of 18.37 and a forward P/E of 12.77, indicating moderate valuation relative to its earnings. The price-to-book ratio of 2.84 suggests the market values the company’s assets at a premium, while the price-to-sales ratio of 0.42 points to a potentially undervalued stock in terms of revenue. These metrics make it a company worth considering for investors seeking stability in the healthcare distribution sector.